AGÕæÈ˹ٷ½

STOCK TITAN

Vyne Therapeutics Inc SEC Filings

VYNE NASDAQ

Welcome to our dedicated page for Vyne Therapeutics SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing Vyne Therapeutics� SEC disclosures can feel like decoding lab notes—clinical trial amendments, BET inhibitor research costs, and equity raises are scattered across hundreds of pages. If you have ever asked, “Where do I find the details of Vyne Therapeutics� latest Phase 2 update?� or hunted for Vyne Therapeutics insider trading Form 4 transactions, you know the challenge.

Stock Titan solves it. Our AI-powered summaries translate R&D jargon into plain English, flagging cash-runway metrics in the Vyne Therapeutics quarterly earnings report 10-Q filing and explaining risk factors in the Vyne Therapeutics annual report 10-K simplified. AGÕæÈ˹ٷ½-time alerts push Vyne Therapeutics Form 4 insider transactions real-time to your dashboard, while “understanding Vyne Therapeutics SEC documents with AIâ€� guides break down every Vyne Therapeutics 8-K material events explained—from trial readouts to licensing deals. Need board-level context? The Vyne Therapeutics proxy statement executive compensation section highlights stock options for scientific leadership, and our platform links each Vyne Therapeutics executive stock transactions Form 4 back to those incentives.

Comprehensive coverage means no document is missed�10-K, 10-Q, S-3, S-8, or 13D. Investors use our tools to (i) compare quarter-over-quarter R&D spend, (ii) monitor dilution risk ahead of capital raises, and (iii) spot management’s confidence via �Vyne Therapeutics earnings report filing analysis.� Whether you are a dermatologist tracking BD2-selective breakthroughs or an analyst modeling cash burn, Stock Titan delivers Vyne Therapeutics SEC filings explained simply, saving hours and sharpening decisions.

Rhea-AI Summary

Novanta Inc. (NASDAQ: NOVT) entered into a Fourth Amended & Restated Credit Agreement on 27 June 2025 that replaces its 2019 facility scheduled to mature in March 2027. The new agreement provides an aggregate senior secured credit capacity of approximately US$1.0 billion, broken down into:

  • â‚�65.31 million 5-year Euro-denominated term loan
  • $75 million 5-year US-dollar term loan
  • $850 million 5-year revolving credit facility

The maturity is extended to June 2030, and an uncommitted accordion feature can raise total commitments by an additional $350 million, subject to customary conditions. Interest is set at (i) Base Rate + 0�0.75 ppt or (ii) SOFR/SONIA/EURIBOR + 1.00�1.75 ppt, with pricing tied to the company’s consolidated leverage ratio. A commitment fee applies to unused revolver capacity.

Key financial covenants tested quarterly include: (1) maximum consolidated leverage ratio of 3.5× (step-up to 4.0× for four quarters following qualifying acquisitions >= $50 million) and (2) minimum fixed-charge coverage ratio of 1.25×. The facilities are secured by senior liens on substantially all assets of Novanta and certain subsidiaries and contain customary negative covenants on mergers, asset sales, indebtedness, investments and liens.

Required quarterly principal amortization begins September 2025 for the Euro term loan and September 2026 for the US term loan, with final balloon payments due at maturity. Prepayments from asset sales, casualty events or incremental debt are mandatory, while voluntary prepayments and commitment reductions are permitted without premium.

Outstanding borrowings under the prior facility were $392.4 million as of 28 March 2025. The new structure enhances liquidity headroom, extends tenor, and provides interest-rate optionality, but also secures the debt and maintains leverage limits that investors should monitor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Novanta Inc. (NASDAQ: NOVT) entered into a Fourth Amended & Restated Credit Agreement on 27 June 2025 that replaces its 2019 facility scheduled to mature in March 2027. The new agreement provides an aggregate senior secured credit capacity of approximately US$1.0 billion, broken down into:

  • â‚�65.31 million 5-year Euro-denominated term loan
  • $75 million 5-year US-dollar term loan
  • $850 million 5-year revolving credit facility

The maturity is extended to June 2030, and an uncommitted accordion feature can raise total commitments by an additional $350 million, subject to customary conditions. Interest is set at (i) Base Rate + 0�0.75 ppt or (ii) SOFR/SONIA/EURIBOR + 1.00�1.75 ppt, with pricing tied to the company’s consolidated leverage ratio. A commitment fee applies to unused revolver capacity.

Key financial covenants tested quarterly include: (1) maximum consolidated leverage ratio of 3.5× (step-up to 4.0× for four quarters following qualifying acquisitions >= $50 million) and (2) minimum fixed-charge coverage ratio of 1.25×. The facilities are secured by senior liens on substantially all assets of Novanta and certain subsidiaries and contain customary negative covenants on mergers, asset sales, indebtedness, investments and liens.

Required quarterly principal amortization begins September 2025 for the Euro term loan and September 2026 for the US term loan, with final balloon payments due at maturity. Prepayments from asset sales, casualty events or incremental debt are mandatory, while voluntary prepayments and commitment reductions are permitted without premium.

Outstanding borrowings under the prior facility were $392.4 million as of 28 March 2025. The new structure enhances liquidity headroom, extends tenor, and provides interest-rate optionality, but also secures the debt and maintains leverage limits that investors should monitor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Novanta Inc. (NASDAQ: NOVT) entered into a Fourth Amended & Restated Credit Agreement on 27 June 2025 that replaces its 2019 facility scheduled to mature in March 2027. The new agreement provides an aggregate senior secured credit capacity of approximately US$1.0 billion, broken down into:

  • â‚�65.31 million 5-year Euro-denominated term loan
  • $75 million 5-year US-dollar term loan
  • $850 million 5-year revolving credit facility

The maturity is extended to June 2030, and an uncommitted accordion feature can raise total commitments by an additional $350 million, subject to customary conditions. Interest is set at (i) Base Rate + 0�0.75 ppt or (ii) SOFR/SONIA/EURIBOR + 1.00�1.75 ppt, with pricing tied to the company’s consolidated leverage ratio. A commitment fee applies to unused revolver capacity.

Key financial covenants tested quarterly include: (1) maximum consolidated leverage ratio of 3.5× (step-up to 4.0× for four quarters following qualifying acquisitions >= $50 million) and (2) minimum fixed-charge coverage ratio of 1.25×. The facilities are secured by senior liens on substantially all assets of Novanta and certain subsidiaries and contain customary negative covenants on mergers, asset sales, indebtedness, investments and liens.

Required quarterly principal amortization begins September 2025 for the Euro term loan and September 2026 for the US term loan, with final balloon payments due at maturity. Prepayments from asset sales, casualty events or incremental debt are mandatory, while voluntary prepayments and commitment reductions are permitted without premium.

Outstanding borrowings under the prior facility were $392.4 million as of 28 March 2025. The new structure enhances liquidity headroom, extends tenor, and provides interest-rate optionality, but also secures the debt and maintains leverage limits that investors should monitor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is offering Autocallable Barrier Securities maturing 6 July 2027 with a total face amount of $922,000 (1,000-denomination). The unsecured notes are linked to the worst performer of three U.S. equity indices: Nasdaq-100 (22,679.01), Russell 2000 (2,175.035) and S&P 500 (6,204.95).

Key mechanics: 1) Automatic early redemption on 30 Jun 2026 if every index closes at or above its initial level, paying principal plus a 12 % premium ($1,120). 2) If not called, final payout on 30 Jun 2027 depends solely on the worst performer: â€� Appreciation participates at a 300 % upside rate. â€� If the worst performer is â‰� initial but â‰� 70 % barrier, only principal is returned. â€� If it falls below the 70 % barrier, investors lose 1 % of principal for each 1 % decline, up to total loss.

The notes do not pay coupons, are not listed, and carry the credit risk of both CGMHI and Citi. Issue price is $1,000, but the internal estimated value is $980.60; underwriting fee up to $10 per note. CGMI will make a secondary market on a best-efforts basis only.

Risk highlights include potential total loss of investment, reliance on a single worst-performing index, high valuation sensitivity on only two observation dates, liquidity constraints, small-cap volatility in Russell 2000, and uncertain tax treatment. The modest offering size and routine structure suggest limited impact on Citi’s overall financials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Vyne Therapeutics (VYNE)?

The current stock price of Vyne Therapeutics (VYNE) is $1.51 as of July 2, 2025.

What is the market cap of Vyne Therapeutics (VYNE)?

The market cap of Vyne Therapeutics (VYNE) is approximately 22.8M.

What is the primary focus of Vyne Therapeutics Inc?

Vyne Therapeutics Inc focuses on developing innovative therapies for immuno-inflammatory conditions, particularly in dermatologic applications such as acne, rosacea, and vitiligo.

Which therapeutic platforms does the company utilize?

The company employs both topical and oral therapeutic platforms, with a major emphasis on selective BET inhibitors, leveraging its proprietary InhiBET technology to target specific inflammatory pathways.

What distinguishes Vyne Therapeutics from other biopharmaceutical companies?

Vyne Therapeutics distinguishes itself through its focus on high unmet needs in immuno-inflammatory diseases and its innovative approach to BET inhibition, achieving greater selectivity to potentially improve patient safety and efficacy profiles.

How is the company advancing its product pipeline?

The company is advancing its product pipeline through rigorous clinical trials and preclinical research, evaluating the safety, tolerability, and pharmacodynamics of its novel compounds in various immuno-inflammatory conditions.

What types of conditions are targeted by Vyne’s therapies?

Vyne’s therapies target a spectrum of conditions including dermatologic disorders like acne vulgaris, rosacea, and vitiligo, as well as other chronic inflammatory diseases linked to immune dysregulation.

How does Vyne ensure scientific and clinical rigor?

The company maintains high scientific and clinical standards by adhering to transparent clinical trial protocols, securing intellectual property, and continuously refining its approach based on detailed biomarker and pharmacodynamic analyses.

What is the significance of BET inhibitors in Vyne’s research?

BET inhibitors are central to Vyne’s research as they regulate gene transcription involved in inflammatory responses. By targeting the BD2 bromodomain selectively, Vyne aims to achieve effective modulation of immune responses with reduced systemic exposure.

Where is Vyne Therapeutics headquartered?

Vyne Therapeutics Inc is headquartered in Bridgewater, New Jersey, which serves as a strategic base for its clinical and research operations.
Vyne Therapeutics Inc

NASDAQ:VYNE

VYNE Rankings

VYNE Stock Data

22.83M
14.90M
8.17%
51.02%
0.81%
Biotechnology
Pharmaceutical Preparations
United States
BRIDGEWATER